Skip to Main Content

To tackle the runaway opioid addiction crisis, some drug makers have tried to make pain pills harder to abuse without changing the opioid molecule itself. This strategy often misfires: People figure out ways to bypass the abuse-resistant technology, allowing the unmodified opioid to enter the brain quickly, resulting in a euphoric high.

Clinical trial data released Tuesday bolsters the case for a different approach: Changing the opioid molecule itself. That’s what Nektar Therapeutics is doing with an experimental opioid tablet, known as NKTR-181, that’s designed to cross the blood-brain barrier more slowly. The goal: relieve pain, but with less euphoria and a lower potential for abuse.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.